The Latest Breaking News from Ocular rapeutix

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Benzinga · Sep 27, 2022

Ocular Therapeutix's Return On Capital Employed Overview

Ocular Therapeutix (NASDAQ:OCUL) brought in sales totaling $13.19 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 225.77%, resulting in a loss of $12.54 million.

Benzinga · Jun 6, 2022

Expert Ratings for Ocular Therapeutix

Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 10, 2022